CA3157387A1 - Optimized gip peptide analogues - Google Patents

Optimized gip peptide analogues Download PDF

Info

Publication number
CA3157387A1
CA3157387A1 CA3157387A CA3157387A CA3157387A1 CA 3157387 A1 CA3157387 A1 CA 3157387A1 CA 3157387 A CA3157387 A CA 3157387A CA 3157387 A CA3157387 A CA 3157387A CA 3157387 A1 CA3157387 A1 CA 3157387A1
Authority
CA
Canada
Prior art keywords
gip
seq
amino acid
peptide analogue
cex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3157387A
Other languages
English (en)
French (fr)
Inventor
Mette Marie Rosenkilde
Alexander Hovard SPARRE-ULRICH
Ditte Riber
Samra Joke SANNI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antag Therapeutics Aps
Original Assignee
Sanni Samra Joke
Sparre Ulrich Alexander Hovard
Antag Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Application filed by Sanni Samra Joke, Sparre Ulrich Alexander Hovard, Antag Therapeutics Aps filed Critical Sanni Samra Joke
Publication of CA3157387A1 publication Critical patent/CA3157387A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3157387A 2019-12-03 2020-12-03 Optimized gip peptide analogues Pending CA3157387A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues
EPPCT/EP2019/083506 2019-12-03
EP20179259 2020-06-10
EP20179259.5 2020-06-10
PCT/EP2020/084487 WO2021110845A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Publications (1)

Publication Number Publication Date
CA3157387A1 true CA3157387A1 (en) 2021-06-10

Family

ID=71083547

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3157387A Pending CA3157387A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Country Status (9)

Country Link
US (1) US20250346647A2 (https=)
EP (1) EP4069719A1 (https=)
JP (2) JP7788376B2 (https=)
KR (1) KR20220108064A (https=)
AU (1) AU2020398675A1 (https=)
CA (1) CA3157387A1 (https=)
IL (1) IL293249A (https=)
MX (1) MX2022006737A (https=)
WO (1) WO2021110845A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139106A3 (en) * 2022-01-18 2023-09-07 Novo Nordisk A/S Long-acting gipr antagonists

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021212A (ko) * 2021-06-10 2024-02-16 안타그 테라퓨틱스 에이피에스 비만 및 비만-관련 장애의 치료
UY40349A (es) * 2022-07-13 2024-01-31 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Agonista dual de glp-1/gip, método de preparación y uso del mismo
WO2025259957A1 (en) * 2024-06-14 2025-12-18 Eli Lilly And Company Compositions and methods for improving insulin sensitivity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0606992A2 (pt) * 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
AU2007284365A1 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
KR101417873B1 (ko) * 2008-08-07 2014-07-09 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체
JP2011530507A (ja) * 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドアナログ
JP6228187B2 (ja) * 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
US10968266B2 (en) * 2014-09-05 2021-04-06 University Of Copenhagen GIP peptide analogues
PL3630806T3 (pl) * 2017-05-31 2024-05-13 The University Of Copenhagen Analogi peptydów gip o długotrwałym działaniu
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN121449721A (zh) * 2018-12-03 2026-02-03 安泰博医药 经修饰的gip肽类似物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139106A3 (en) * 2022-01-18 2023-09-07 Novo Nordisk A/S Long-acting gipr antagonists

Also Published As

Publication number Publication date
WO2021110845A1 (en) 2021-06-10
EP4069719A1 (en) 2022-10-12
JP2023505441A (ja) 2023-02-09
KR20220108064A (ko) 2022-08-02
US20250346647A2 (en) 2025-11-13
IL293249A (en) 2022-07-01
JP2025172864A (ja) 2025-11-26
JP7788376B2 (ja) 2025-12-18
AU2020398675A1 (en) 2022-05-26
CN114761420A (zh) 2022-07-15
US20230416330A1 (en) 2023-12-28
MX2022006737A (es) 2022-06-14

Similar Documents

Publication Publication Date Title
US12187773B2 (en) Modified GIP peptide analogues
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
JP6657230B2 (ja) インクレチン−インスリンコンジュゲート
US9764004B2 (en) Glucagon receptor agonists
KR102824306B1 (ko) 인크레틴 유사체 및 그의 용도
CN111491658A (zh) 肠促胰岛素类似物及其用途
JP7788376B2 (ja) 最適化されたｇｉｐペプチド類縁体
RS61107B1 (sr) Glukagon i glp-1 ko-agonist jedinjenja
CN101855240A (zh) 改进的胰岛淀粉样多肽衍生物
US11572399B2 (en) Long-acting GIP peptide analogues
JP2011525895A (ja) アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
KR20250140094A (ko) Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도
RU2858286C2 (ru) Оптимизированные пептидные аналоги gip
CN114761420B (zh) 优化的gip肽类似物
RU2817673C2 (ru) Модифицированные аналоги GIP пептида
EA043950B1 (ru) Аналоги инкретина и их применение

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241120

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241120

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250226

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTERNAL INVESTIGATION REQUEST

Effective date: 20260310